JBM (Healthcare) Limited
HKSE 2161.HK
JBM (Healthcare) Limited EBITDA Margin for the year ending March 31, 2024: 34.04%
-
JBM (Healthcare) Limited EBITDA Margin for the year ending March 31, 2023 was 21.41%, a 3.34% change year over year.
-
JBM (Healthcare) Limited EBITDA Margin for the year ending March 31, 2022 was 20.72%, a -28.15% change year over year.
-
JBM (Healthcare) Limited EBITDA Margin for the year ending March 31, 2021 was 28.83%, a 25.43% change year over year.
-
JBM (Healthcare) Limited EBITDA Margin for the year ending March 31, 2020 was 22.99%, a -26.52% change year over year.
| Date | EBITDA Margin | EBIT Margin | Depreciation and Amortization | EBIT |
|---|
Don’t Miss A Beat
| CEO | Mr. Yat Wai Wong |
| IPO Date | Feb. 5, 2021 |
| Location | Hong Kong |
| Headquarters | Unit 2303-07, Tower 1 |
| Employees | 279 |
| Sector | Health Care |
| Industries | |
JBM (Healthcare) Limited, an investment holding company, develops, manufactures, markets, distributes, and sells healthcare and wellness products in Asia. The company offers consumer healthcare and proprietary Chinese medicines, such as over-the-counter medicines, and medicated and non-medicated solutions, as well as diagnostic devices; and pharmaceutical products. It is also involved in the trading, wholesaling, and retailing of Chinese medicines; trading of medical supplies and pharmaceutical products; and sale of healthcare and herbal products. The company was incorporated in 2020 and is headquartered in Kwun Tong, Hong Kong. JBM (Healthcare) Limited is a subsidiary of JBM Group (BVI) Limited.
Past 5 years
USD 0.34
StockViz Staff
February 4, 2025
Any question? Send us an email